Acknowledgements This work was supported by the European Community under the Innovative Medicine Initiative project MIP-DILI (grant agreement number 115336, to SH, DK and JT), by the BMBF (Her2Low, No
Saitou M, Furuse M, Sasaki H, Schulzke JD, Fromm M, Takano H, et al
If the widespread use of weight-loss drugs has a meaningful impact on longevity, there are a variety of ways that they could disrupt healthcare. Consider, for example, that while obese people generally spend as much as $3,000 more per year on health care than the general population, it doesn't necessarily mean that lower obesity rates reduce healthcare spending
The SELECT trial showed a 20% reduction in MACE with semaglutide in people with overweight/obesity and established CVD